2013-09-17 11:00:02 - Kasper Lamberth, Department Head for Immunogenicity Prediction and Tolerance at Biopharmaceutical Research Unit, Novo Nordisk A/S to Give a Featured Presentation at the Immunogenicity and Immunotoxicity Conference (January 29-31, 2014 in San Diego, CA)
Kasper Lamberth Head of the Immunogenicity Prediction & Tolerance Department at Novo Nordisk A/S will give a Featured Presentation on “Using Immunogenicity Prediction Tools to Identify CD4+ T-cell Epitopes in an rFVIIa Analogue Giving Rise to ADAs?” at the 2nd Annual Immunogenicity and Immunotoxicity Conference to be held on January 29-31, 2014 in San Diego, CA by GTC.
Dr. Lamberth will discuss the development of an rFVIIa analogue (Vatreptacog alfa) which was recently discontinued due to the development of ADAs in a phase 3 trial. The rFVIIa analogue has three mutations compared to endogenous rFVIIa and by employing different immunogenicity prediction tools we are trying to evaluate if these tools are able to predict the formation of ADAs in the
clinic. Dr. Lamberth will present data from in silico and ex vivo immunogenicity prediction tools on full length molecules and on peptides with different length.
Kasper Lamberth, Ph.D., has very recently transitioned to the role as Department Head for Immunogenicity Prediction and Tolerance at Biopharmaceutical Research Unit, Novo Nordisk A/S. Dr. Lamberth joined Novo Nordisk 5 years ago and during this time he has worked with development of immunogenicity prediction tools as well as high throughput screening technologies. Prior to Novo Nordisk A/S, Dr. Lamberth worked for eight years with predictive immunogenicity tools, especially with MHC polymorphism and the identification of T-cell epitopes within the field of infectious diseases at Copenhagen University. Dr. Lamberth holds a MS in Biochemistry and a PhD in Immunology, both from Copenhagen University.
The Immunogenicity and Immunotoxicity Conference will provide guests with a better understanding of the ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Guests will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.
This conference is also part of the Novel Immunotherapeutics Summit 2014, which consists of this track and three other tracks:
I. 6th Immunotherapeutics and Immunomonitoring
II. Innate Immunity
III. 12th Cytokines and Inflammation
For more information, please visit www.gtcbio.com/igit